OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Breast Cancer Overview

Breast Cancer — All 64 Unranked Reference Options

Provenance SHA-256: 94b1c2d347d08e05 · Protocol drug dosing hard-excluded in Patient Edition.

Option / Regimen FamilyCategory & StatusCurated Source IDs
Breast and axillary surgery planning
Multidisciplinary review of breast and axillary local treatment.
Local care
Care pathway
nci
Postoperative radiation review
Review breast, chest wall and nodal radiation needs with the local team.
Local care
Care pathway
nci
Adjuvant endocrine treatment
Confirm endocrine agent, menopausal physiology and ovarian suppression where appropriate.
Endocrine therapy
Care pathway
nci
Preoperative aromatase inhibitor review
Consider endocrine downstaging in a selected postmenopausal patient.
Endocrine therapy
Care pathway
nci
Early chemotherapy review
Choose a regimen after recurrence-risk, comorbidity and genomic-assay review where applicable.
Chemotherapy
Care pathway
nci
Abemaciclib plus adjuvant endocrine therapy
High-risk node-positive disease under the revised monarchE label.
Adjuvant targeted therapy
FDA-approved
abema, abema_label, verzenio_coverage_20261109
Ribociclib plus adjuvant aromatase inhibitor
Stage II or III high-risk disease after explicit NATALEE risk review.
Adjuvant targeted therapy
FDA-approved
ribo_adj, ribo_label, kisqali_coverage_20261109
Adjuvant olaparib
Germline BRCA-associated high-risk disease after chemotherapy and definitive local care.
Adjuvant targeted therapy
FDA-approved
olaparib
T-DXd followed by taxane, trastuzumab and pertuzumab
Newly approved neoadjuvant sequence for HER2-positive stage II–III disease.
Neoadjuvant HER2 therapy
FDA-approved
tdxd_early, enhertu
Trastuzumab, pertuzumab and chemotherapy before surgery
HER2-positive disease meeting tumor-size or nodal criteria.
Neoadjuvant HER2 therapy
FDA-approved
perjeta
Trastuzumab, pertuzumab and adjuvant chemotherapy review
Review a HER2-directed adjuvant course for high-risk disease.
Adjuvant HER2 therapy
FDA-approved
perjeta
T-DXd after residual invasive HER2-positive disease
Adjuvant T-DXd after trastuzumab and taxane-based neoadjuvant treatment.
Post-neoadjuvant HER2 therapy
FDA-approved
tdxd_early, enhertu
Pembrolizumab with chemotherapy, then postoperative pembrolizumab
Review the complete KEYNOTE-522 perioperative course.
Perioperative TNBC therapy
FDA-approved
kn522_label, kn522, kn522_os
Complete planned postoperative pembrolizumab
Continuation of an established perioperative regimen after surgery.
Post-neoadjuvant TNBC therapy
FDA-approved
kn522_label
Adjuvant capecitabine for residual TNBC
Evidence-supported off-label review after residual disease following chemotherapy.
Post-neoadjuvant chemotherapy
Evidence-supported off-label
createx, dpyd
Ribociclib plus an aromatase inhibitor
Initial endocrine-based option with appropriate gonadal suppression.
Initial endocrine-based therapy
FDA-approved
ribo_label, kisqali_coverage_20261109
Inavolisib, palbociclib and fulvestrant
Endocrine-resistant PIK3CA-mutated recurrence after adjuvant endocrine therapy.
PI3K-directed therapy
FDA-approved
inavo, inavo_label
Capivasertib plus fulvestrant
Alteration-directed option after progression on at least one endocrine-based regimen in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy.
AKT-directed therapy
FDA-approved
capi, capi_label, capi_label_i9
Elacestrant
Oral endocrine option in the labeled adult male or postmenopausal population.
ESR1-directed endocrine therapy
FDA-approved
elacestrant, elacestrant_label
Vepdegestrant
Approved oral estrogen-receptor degrader after endocrine progression.
ESR1-directed endocrine therapy
FDA-approved
vep, vep_label
Imlunestrant plus abemaciclib
Endocrine/CDK4/6 combination after qualifying progression.
ESR1-directed combination
FDA-approved
imlu_abema, imlu_label
Camizestrant plus the ongoing CDK4/6 inhibitor
Accelerated approval: switch the endocrine partner upon ESR1 detection before clinical progression; confirmatory clinical benefit remains pending.
On-treatment molecular switch
FDA accelerated approval
cami, cami_label
Gedatolisib, fulvestrant and palbociclib
Option when a reviewed test detects no PIK3CA mutation, after progression on or after at least one line of endocrine therapy in the metastatic setting.
PI3K/mTOR-directed therapy
FDA-approved
geda, geda_label
Gedatolisib and fulvestrant
Option when a reviewed test detects no PIK3CA mutation, after progression on or after at least one line of endocrine therapy in the metastatic setting.
PI3K/mTOR-directed therapy
FDA-approved
geda, geda_label
T-DXd after endocrine progression in HER2-low or ultralow disease
Separate low and ultralow pathology from IHC 0 without staining.
Antibody-drug conjugate
FDA-approved
tdxd_low, enhertu
Datopotamab deruxtecan after endocrine therapy and advanced chemotherapy
Prior endocrine-based and advanced chemotherapy must be documented.
Antibody-drug conjugate
FDA-approved
dato_hr, dato_label
Sacituzumab govitecan after multiple HR-positive therapies
Later-line endocrine-treated disease after the defined exposure review.
Antibody-drug conjugate
FDA-approved
sg_hr, sg_label, trodelvy_coverage_20261109
Olaparib for germline BRCA-associated metastatic disease
Review germline result, prior chemotherapy and endocrine history.
PARP inhibitor
FDA-approved
olaparib
T-DXd plus pertuzumab first line
First-line HER2-positive option in the approved setting.
Initial HER2 therapy
FDA-approved
tdxd_first, enhertu
Taxane, trastuzumab and pertuzumab first line
Established HER2-directed chemotherapy option.
Initial HER2 therapy
FDA-approved
perjeta, tdxd_first
Palbociclib plus HER2-directed and endocrine maintenance
After nonprogressing taxane/HER2 induction in HR-positive disease.
HER2 maintenance
FDA-approved
palbo_maint, palbo_label
Tucatinib plus trastuzumab and pertuzumab maintenance
Maintenance following nonprogressing THP induction.
HER2 maintenance
FDA-approved
tuca_maint, tuca_label
T-DXd after prior HER2 therapy
HER2-positive disease after the label-defined prior regimen.
Subsequent HER2 therapy
FDA-approved
enhertu, destiny-breast02
Tucatinib, trastuzumab and capecitabine
Option after prior metastatic HER2 therapy, including selected patients with brain metastases.
Subsequent HER2 therapy
FDA-approved
tuca_later, dpyd, tuca_label, capecitabine_i8
Pembrolizumab plus chemotherapy for PD-L1-positive TNBC
PD-L1 CPS-selected initial advanced TNBC option.
Initial TNBC therapy
FDA-approved
kn355, kn522_label
Sacituzumab govitecan plus pembrolizumab first line
New first-line option for PD-L1 CPS-selected TNBC.
Initial TNBC therapy
FDA-approved
sg_first, sg_label
Sacituzumab govitecan first line without checkpoint therapy
Requires an explicit clinician finding that checkpoint therapy is unsuitable.
Initial TNBC therapy
FDA-approved
sg_first, sg_label, trodelvy_coverage_20261109
Datopotamab deruxtecan for checkpoint-ineligible TNBC
The TNBC label is not restricted to first line. Prior treatment or ADC exposure requires a separate evidence review; TROPION-Breast02 studied untreated advanced disease.
TNBC therapy with source-qualified discussion
FDA-approved
dato_tnbc, dato_label
T-DXd for HER2-low disease after chemotherapy
HER2-low disease after qualifying chemotherapy or early recurrence.
Antibody-drug conjugate
FDA-approved
enhertu
T-DM1 after residual invasive HER2-positive disease
Established adjuvant HER2 option after residual disease following taxane and trastuzumab.
Post-neoadjuvant HER2 therapy
FDA-approved
tdm1, tdxd_early, kadcyla_coverage_20261109
Imlunestrant
Oral endocrine monotherapy after progression in ESR1-mutated disease.
ESR1-directed endocrine monotherapy
FDA-approved
imlu, imlu_label
Adjuvant trastuzumab-based treatment review
Select postoperative HER2-directed care using tumor size, nodes and comorbidities.
Adjuvant HER2 therapy
Care pathway
nci, perjeta
Adjuvant paclitaxel and trastuzumab for small node-negative tumors
Review the less-intensive APT regimen for documented small node-negative HER2-positive disease.
Adjuvant HER2 therapy
Source-supported regimen review
apt, nci, apt_initial
Sacituzumab govitecan after prior triple-negative therapies
Review after at least two prior systemic therapies, including at least one for metastatic disease.
Antibody-drug conjugate
FDA-approved
sg_label, trodelvy_coverage_20261109
Alpelisib plus fulvestrant
The adult label permits use after progression on an endocrine-based regimen with a confirmed PIK3CA alteration. SOLAR-1 numerical applicability separately requires its AI-progressed, postmenopausal/male population.
PI3K-directed therapy
FDA-approved
alpelisib_label
Ribociclib plus fulvestrant
Adult HR-positive/HER2-negative advanced or metastatic disease; initial endocrine-based treatment or progression on endocrine treatment. Appropriate gonadal suppression and patient safety review.
Source-supported additional alternative
FDA-approved
kisqali, monaleesa3_updated
Abemaciclib plus fulvestrant
Adult HR-positive/HER2-negative advanced/metastatic disease with progression following endocrine treatment; gonadal suppression when indicated.
Source-supported additional alternative
FDA-approved
verzenio, monarch2_os
Palbociclib plus fulvestrant
Adult HR-positive/HER2-negative advanced/metastatic disease progressing following endocrine treatment; appropriate gonadal suppression.
Source-supported additional alternative
FDA-approved
ibrance, paloma3_primary
HER2-directed and endocrine maintenance without added escalation
Not a new standalone approval claim. Source-supported standard-control pathway after nonprogressing HER2-directed induction in HR-positive/HER2-positive advanced disease, with a reviewed endocrine partner and appropriate suppression.
Source-supported additional alternative
Source-supported maintenance pathway; no standalone approval claim
ibrance, patina_registry, patina_primary
Everolimus plus exemestane
Postmenopausal women with advanced HR-positive/HER2-negative disease after failure of letrozole or anastrozole. Do not substitute generic AI exposure or silently generalize to males/premenopausal patients.
Source-supported additional alternative
FDA-approved
afinitor, bolero2_os
Talazoparib for germline BRCA-associated advanced disease
Adult deleterious/suspected deleterious germlineBRCA-mutated HER2-negative locally advanced/metastatic disease with therapy-specific authorized companion test. Do not import olaparib's chemotherapy/endocrine prerequisites into this label.
Source-supported additional alternative
FDA-approved
talzenna, embraca_final
Abemaciclib plus an aromatase inhibitor
Initial endocrine-based option in adult HR-positive/HER2-negative advanced disease with appropriate gonadal suppression.
Initial endocrine-based alternative
FDA-approved
verzenio_coverage_20261109
Palbociclib plus an aromatase inhibitor
Initial endocrine-based option in adult HR-positive/HER2-negative advanced disease with appropriate gonadal suppression.
Initial endocrine-based alternative
FDA-approved
ibrance_coverage_20261109
Capecitabine monotherapy for advanced breast cancer
Single-agent review when anthracycline- or taxane-containing chemotherapy is not indicated.
Conventional chemotherapy alternative
FDA-approved within reviewed label context
capecitabine_i8
Eribulin for previously treated metastatic breast cancer
Label use requires at least two prior metastatic chemotherapy regimens and prior anthracycline plus taxane in adjuvant or metastatic treatment.
Conventional chemotherapy alternative
FDA-approved within reviewed label context
eribulin_i8
T-DM1 (ado-trastuzumab emtansine) after trastuzumab and a taxane
Single-agent option for metastatic HER2-positive disease after trastuzumab and a taxane, given for metastatic disease or with recurrence during or within six months of adjuvant treatment.
Subsequent HER2 therapy
FDA-approved
tdm1
Neratinib plus capecitabine after two or more anti-HER2 regimens for metastatic disease
Oral combination for advanced or metastatic HER2-positive disease after two or more anti-HER2 regimens given for metastatic disease.
Subsequent HER2 therapy
FDA-approved
nerlynx_label, dpyd
Extended adjuvant neratinib after trastuzumab-based treatment
One year of oral treatment that follows completed adjuvant trastuzumab-based treatment in early HER2-positive disease.
Adjuvant HER2 therapy
FDA-approved
nerlynx_label
Gemcitabine plus paclitaxel, first line after adjuvant anthracycline
First-line chemotherapy combination for metastatic disease after adjuvant anthracycline chemotherapy, or when an anthracycline was contraindicated.
Conventional chemotherapy alternative
FDA-approved
gemcitabine_label
Albumin-bound paclitaxel after earlier chemotherapy
Single-agent taxane after combination chemotherapy for metastatic disease has failed, or after relapse within 6 months of adjuvant chemotherapy.
Conventional chemotherapy alternative
FDA-approved
abraxane_label
Carboplatin for germline BRCA-associated advanced triple-negative disease (off-label)
Off-label single-agent platinum for advanced triple-negative disease with a germline BRCA1 or BRCA2 pathogenic variant, supported by the TNT trial.
Conventional chemotherapy alternative
Evidence-supported off-label
tnt_2018, carboplatin_label
Switch to fulvestrant with continued palbociclib (off-label)
Off-label switch from the aromatase inhibitor to fulvestrant, keeping palbociclib, when an ESR1 mutation appears in blood without disease progression; supported by the PADA-1 trial.
On-treatment molecular switch
Evidence-supported off-label
pada1_2022, faslodex_label
Adjuvant T-DM1 for stage I HER2-positive disease (off-label)
Off-label one-year T-DM1 course after surgery for stage I HER2-positive disease, supported by the ATEMPT trial.
Adjuvant HER2 therapy
Evidence-supported off-label
atempt_2021, nci_pdq_breast_20250425, tdm1, registry_NCT01853748
Docetaxel, carboplatin, trastuzumab and pertuzumab before surgery (TCHP)
Six preoperative every-3-week cycles of pertuzumab, trastuzumab, docetaxel (75 mg/m2) and carboplatin (AUC 6) without anthracycline.
Neoadjuvant HER2 therapy
FDA-approved
perjeta, herceptin_label, docetaxel_label, carboplatin_label